Aernoud Fiolet

134 Chapter 5 GlaxoSmithKline, Janssen, and Sanofi Aventis; Dr. Alings, receiving consulting fees from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, Pfizer, Portola, and Sanofi; and Dr. Cornel, receiving advisory board fees from AstraZeneca, advisory board fees and fees for serving as national lead investigator fromAmgen, and fees for serving as chair of an end-point adjudication committee from IQVIA. No other potential conflict of interest relevant to this article was reported. Drs. Nidorf and Fiolet and Drs. Mosterd, Cornel, and Thompson contributed equally to this article. This article was published on August 31, 2020, at NEJM.org. A data sharing statement provided by the authors is available with the full text of this article at NEJM.org . We thankall thepatients for theirparticipation in the trial; the trial investigators and coordinators at all the centers; and the trial monitors and staff from GenesisCare, including Penny Buczec, Denny Craig, Karen Doherty, Louise Ferguson, Louise Nidorf, and Karen Youl, from the Heart and Vascular Research Institute of Sir Charles Gairdner Hospital, including Louise Ferguson, and from the Dutch Network for Cardiovascular Research, including Marjelle van Leeuwen (project manager), Ingrid Groenenberg and Glentino Rodriguez for data management, Erik Stroes, Max Silvis, and Tim de Vries for medical review, and Petra Bunschoten and Wendy Tousain for site monitoring.